NCT06219356 - A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2027

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

GLB-002

Administered orally according to the assigned treatment schedule.

Trial Locations (13)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

100191

RECRUITING

Peking University Third Hospital, Beijing

110004

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

300020

RECRUITING

Tianjing Medical University Cancer Institute and Hospital, Tianjin

310003

RECRUITING

The First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou

330029

RECRUITING

Jiangxi Cancer Hospital, Nanchang

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

410000

RECRUITING

Hunan Cancer Hospital, Changsha

430023

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

030000

RECRUITING

Shanxi Cancer hospital, Taiyuan

All Listed Sponsors

lead

Hangzhou GluBio Pharmaceutical Co., Ltd.

INDUSTRY